Vogel, Arndt;
Grant, Robert C;
Meyer, Tim;
Sapisochin, Gonzalo;
O'Kane, Grainne M;
Saborowski, Anna;
(2023)
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
Hepatology
10.1097/HEP.0000000000000726.
(In press).
Preview |
Text
adjuvant_and_neoadjuvant_therapies_for.690.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Immune-oncology based regimens have shown efficacy in advanced hepatocellular carcinoma and have been implemented as standard of care as first line therapy. Their efficacy, including high response rates, and safety justifies their evaluation in earlier disease stages. Following negative results for adjuvant sorafenib in the global STORM trial in 2015, four global phase 3 trials, featuring different immune checkpoint inhibitor combinations, entered in parallel the race in the adjuvant setting. The IMbrave050 trial, comparing adjuvant atezolizumab in combination with bevacizumab to active surveillance following curative-intent resection or ablation, was the first to report, fast-tracking the results of the first interim analysis and demonstrating an improvement in recurrence free survival. The trial has provoked a discussion on the horizon of expectations from adjuvant treatment and the clinical relevance of efficacy endpoints. Moreover, major pathological responses reported from early phase 2 data in the neoadjuvant setting provide a strong rational for the evaluation of these concepts in phase 3 trials. In this review, we summarize current evidence and outline future directions for systemic therapies in early-stage hepatocellular carcinoma.
| Type: | Article |
|---|---|
| Title: | Adjuvant and neoadjuvant therapies for hepatocellular carcinoma |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1097/HEP.0000000000000726 |
| Publisher version: | http://doi.org/10.1097/hep.0000000000000726 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Intra-arterial therapies, resection, transplantation, ablation, tyrosine kinase inhibitor, checkpoint inhibitor |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10184779 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
